Nele Fourneau

Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study

Anas Younes, Catherine Thiéblemont, Franck Morschhauser et al. · The Lancet Oncology · 2014 · 253 citations

Medicine, Immunology, Oncology +11

Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study

Anas Younes, Joshua Brody, Cecilia Carpio et al. · The Lancet Haematology · 2019 · 195 citations · Full text

Life Sciences, Immunology, Oncology +15

A Phase I Study of Quisinostat (JNJ-26481585), an Oral Hydroxamate Histone Deacetylase Inhibitor with Evidence of Target Modulation and Antitumor Activity, in Patients with Advanced Solid Tumors

Balaji Venugopal, Richard D. Baird, Rebecca Kristeleit et al. · Clinical Cancer Research · 2013 · 123 citations · Full text

Medicine, Oncology, Pharmacology +15

Quisinostat, bortezomib, and dexamethasone combination therapy for relapsed multiple myeloma

Philippe Moreau, Thierry Façon, Cyrille Touzeau et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2016 · 30 citations

Medicine, Pharmacology, Pharmacotherapy +13

Circulating tumor DNA for comprehensive noninvasive monitoring of lymphoma treated with ibrutinib plus nivolumab

Alessio Bruscaggin, Lodovico Terzi di Bergamo, Valeria Spina et al. · Blood Advances · 2021 · 27 citations · Full text

Medicine, Hematology, Oncology +17